259 related articles for article (PubMed ID: 33136521)
1. CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins.
Jost C; Darowski D; Challier J; Pulko V; Hanisch LJ; Xu W; Mössner E; Bujotzek A; Klostermann S; Umana P; Kontermann RE; Klein C
MAbs; 2020; 12(1):1840709. PubMed ID: 33136521
[TBL] [Abstract][Full Text] [Related]
2. P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.
Darowski D; Jost C; Stubenrauch K; Wessels U; Benz J; Ehler A; Freimoser-Grundschober A; Brünker P; Mössner E; Umaña P; Kobold S; Klein C
Protein Eng Des Sel; 2019 Dec; 32(5):207-218. PubMed ID: 31504896
[TBL] [Abstract][Full Text] [Related]
3. Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells.
Massafra V; Tundo S; Dietzig A; Ducret A; Jost C; Klein C; Kontermann RE; Knoetgen H; Steegmaier M; Romagnani A; Nagel YA
J Immunol; 2021 Jul; 207(2):493-504. PubMed ID: 34215653
[TBL] [Abstract][Full Text] [Related]
4. Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.
Kroll KT; Mata MM; Homan KA; Micallef V; Carpy A; Hiratsuka K; Morizane R; Moisan A; Gubler M; Walz AC; Marrer-Berger E; Lewis JA
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2305322120. PubMed ID: 37603766
[TBL] [Abstract][Full Text] [Related]
5. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
6. The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy.
Arman I; Haus-Cohen M; Reiter Y
Cells; 2022 Dec; 12(1):. PubMed ID: 36611821
[TBL] [Abstract][Full Text] [Related]
7. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.
Maruta M; Ochi T; Tanimoto K; Asai H; Saitou T; Fujiwara H; Imamura T; Takenaka K; Yasukawa M
Sci Rep; 2019 Sep; 9(1):13293. PubMed ID: 31527633
[TBL] [Abstract][Full Text] [Related]
9. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
[TBL] [Abstract][Full Text] [Related]
10. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
11. Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs.
Anikeeva N; Panteleev S; Mazzanti NW; Terai M; Sato T; Sykulev Y
J Biol Chem; 2021 Sep; 297(3):101033. PubMed ID: 34371020
[TBL] [Abstract][Full Text] [Related]
12. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.
Dahan R; Gebe JA; Preisinger A; James EA; Tendler M; Nepom GT; Reiter Y
J Autoimmun; 2013 Dec; 47():83-93. PubMed ID: 24090977
[TBL] [Abstract][Full Text] [Related]
14. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
Sharma P; Kranz DM
Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
[TBL] [Abstract][Full Text] [Related]
15. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
16. Nanobody-based CAR T cells targeting intracellular tumor antigens.
Li H; Zhong D; Luo H; Shi W; Xie S; Qiang H; Zhu L; Gao L; Liu J; Sun S; Ding Z; Yang X; Lu X
Biomed Pharmacother; 2022 Dec; 156():113919. PubMed ID: 36411612
[TBL] [Abstract][Full Text] [Related]
17. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
Akatsuka Y
Front Immunol; 2020; 11():257. PubMed ID: 32184779
[TBL] [Abstract][Full Text] [Related]
18. TCR-like antibodies targeting autoantigen-mhc complexes: a mini-review.
Li Y; Jiang W; Mellins ED
Front Immunol; 2022; 13():968432. PubMed ID: 35967436
[TBL] [Abstract][Full Text] [Related]
19. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of chimeric antigen receptor of humanized rabbit-derived T cell receptor-like antibody.
Nakamura T; Kobayashi E; Hamana H; Hayakawa Y; Muraguchi A; Hayashi A; Ozawa T; Kishi H
Cancer Sci; 2022 Oct; 113(10):3321-3329. PubMed ID: 35766417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]